1h Free Analyst Time
The Veterinary Antimicrobial Susceptibility Testing Market is projected to reach USD 1.60 Billion in 2026. It is expected to continue growing at a CAGR of 8.78%, reaching USD 2.66 Billion by 2032. Speak directly to the analyst to clarify any post sales queries you may have.
Veterinary antimicrobial susceptibility testing (AST) is becoming a critical pillar of animal health, food safety, and antimicrobial resistance (AMR) stewardship. By determining whether bacterial pathogens from companion animals, livestock, aquaculture, or poultry are susceptible or resistant to specific antimicrobial agents, veterinary AST supports evidence-based treatment decisions and helps reduce unnecessary antibiotic use. The field is shaped by internationally recognized standards and surveillance frameworks, including guidance from the World Organisation for Animal Health, Codex Alimentarius, national veterinary diagnostic standards, and integrated AMR monitoring programs that connect animal, food, human, and environmental data under a One Health approach.
The relevance of veterinary antimicrobial susceptibility testing has increased as resistant zoonotic and foodborne bacteria such as Salmonella, Campylobacter, Escherichia coli, Staphylococcus pseudintermedius, Streptococcus suis, and Pasteurella species remain a concern across animal production systems and clinical veterinary practice. Laboratories are expanding the use of broth microdilution, disk diffusion, agar dilution, gradient diffusion, automated phenotypic systems, and molecular assays to generate actionable results. At the same time, veterinary clinicians, producers, regulators, and diagnostic networks are demanding faster turnaround times, standardized interpretive criteria, quality-controlled workflows, and data interoperability to support responsible antimicrobial use.
Transformative Shifts Reshaping Veterinary AST
The veterinary AST landscape is undergoing a structural shift from episodic testing toward routine, surveillance-linked, and stewardship-oriented diagnostics. Historically, many antimicrobial decisions in veterinary care relied on empirical therapy, farm-level treatment protocols, or delayed laboratory confirmation. This model is changing as AMR action plans, veterinary antimicrobial use restrictions, prescription oversight, and food chain assurance programs encourage culture and susceptibility testing before or during treatment decisions, particularly for recurrent infections, herd outbreaks, and high-value production systems.A second transformation is the movement toward harmonized standards and species-relevant breakpoints. Veterinary AST has long faced challenges where human clinical breakpoints were used inappropriately for animal pathogens or where interpretive criteria were unavailable for specific host-pathogen-drug combinations. Current best practice increasingly emphasizes validated veterinary breakpoints, epidemiological cutoff values, quality control organisms, and standardized reporting language that reflects pharmacokinetics, pharmacodynamics, tissue distribution, and route of administration in target species.
The third major shift is digitalization. Laboratory information systems, electronic veterinary medical records, and AMR surveillance platforms are enabling structured reporting of isolate-level susceptibility results. This supports longitudinal resistance tracking, antimicrobial stewardship benchmarking, outbreak investigation, and risk-based interventions in livestock and companion animal settings. The growing use of rapid diagnostics, molecular resistance marker detection, and automated susceptibility platforms is also reshaping expectations around speed, accuracy, and decision support.
Cumulative Impact of Artificial Intelligence on Veterinary AST
Artificial intelligence is beginning to create cumulative impact across veterinary antimicrobial susceptibility testing by improving data interpretation, workflow efficiency, and surveillance intelligence. In diagnostic laboratories, AI-enabled image analysis can support colony recognition, inhibition zone reading, growth pattern detection, and quality control review, reducing manual variability when systems are properly validated. Machine learning models can also help flag unusual resistance phenotypes, identify likely contamination or mixed culture patterns, and prioritize isolates requiring confirmatory testing.In clinical and production settings, AI can strengthen antimicrobial stewardship by combining AST results with animal species, disease syndrome, prior treatment history, farm management data, vaccination status, and regional resistance trends. This creates an opportunity for decision support tools that recommend when testing is warranted, which antimicrobial panels are most appropriate, and how results should be interpreted in the context of veterinary guidelines. For food animal systems, AI can help detect early AMR signals across farms, slaughter points, feedlot networks, and diagnostic submissions.
However, the value of AI in veterinary AST depends on verified datasets, standardized metadata, transparent model validation, and governance that prevents overreliance on algorithmic outputs. Resistance prediction from genomic data remains promising but must be connected to phenotypic confirmation, clinically relevant breakpoints, and species-specific treatment outcomes. The most defensible AI applications are those that augment trained microbiologists and veterinarians rather than replace laboratory quality systems, antimicrobial stewardship principles, or professional clinical judgment.
Key Regional Insights Across Veterinary AST Adoption
Asia-Pacific is advancing veterinary antimicrobial susceptibility testing through a combination of livestock intensification, aquaculture expansion, companion animal healthcare growth, and national AMR action plans. Countries in the region are strengthening surveillance of foodborne pathogens and antimicrobial use in animals, while diagnostic capacity varies widely between advanced urban laboratories and resource-constrained rural production areas. The region’s large poultry, swine, dairy, and aquaculture sectors create strong demand for standardized AST that can support disease control and prudent antimicrobial use.North America has mature veterinary diagnostic infrastructure, established antimicrobial stewardship programs, and integrated monitoring of resistant bacteria from food animals, retail meat, and humans. The United States and Canada emphasize laboratory quality assurance, veterinary oversight of medically important antimicrobials, and surveillance-linked reporting, supporting adoption of validated phenotypic and molecular AST workflows. Latin America is strengthening veterinary AST through food export requirements, poultry and beef production monitoring, and public health attention to zoonotic resistance, although uneven laboratory access and standardization remain important operational challenges.
Europe is characterized by strong regulatory pressure on antimicrobial use in animals, coordinated AMR monitoring, and extensive implementation of One Health surveillance principles. Restrictions on routine prophylactic use, emphasis on veterinary prescription accountability, and harmonized reporting frameworks support consistent demand for AST in both food animal and companion animal practice. In the Middle East, veterinary AST adoption is shaped by food security priorities, intensive poultry and dairy production, equine medicine, and growing companion animal care, with GCC countries investing in laboratory modernization and biosecurity. Across Africa, veterinary AST is gaining importance as countries address transboundary animal diseases, food safety, zoonotic infections, and antimicrobial stewardship, but capacity building, access to quality-assured laboratories, and workforce training remain essential to improve diagnostic coverage.
Key Group Insights for Veterinary AST Stakeholders
ASEAN’s veterinary antimicrobial susceptibility testing priorities are closely linked to poultry, swine, aquaculture, and food safety programs, with member states increasingly aligning animal health surveillance with national AMR strategies. Differences in laboratory infrastructure, regulatory enforcement, and farm biosecurity create variability in AST adoption, but regional trade and food export requirements continue to encourage standardized testing and reporting.The GCC is advancing veterinary AST through investments in food security, dairy and poultry production, camel and equine health, and centralized laboratory capabilities. Demand is reinforced by import controls, biosecurity initiatives, and the need to manage infectious disease risks in intensive and high-value animal populations. The European Union represents one of the most structured environments for veterinary AST due to harmonized AMR monitoring, restrictions on veterinary antimicrobial use, and strong emphasis on One Health data integration across animal, food, and human health sectors.
BRICS countries represent diverse but influential veterinary AST environments due to their large livestock populations, expanding veterinary services, and growing role in global food supply. China, India, Brazil, Russia, and South Africa face different challenges, ranging from high production density and mixed farming systems to diagnostic access gaps and regional surveillance variability. G7 countries generally have advanced laboratory networks, veterinary prescription controls, and research-driven stewardship programs that support high-quality AST implementation. NATO member countries, many of which overlap with high-income European and North American systems, show strong alignment around biosecurity, food safety, and public health preparedness, making veterinary AST relevant not only to clinical care but also to resilience against zoonotic and transboundary disease threats.
Key Country Insights Shaping Veterinary AST Demand
The United States has a well-developed veterinary diagnostic laboratory network and established AMR surveillance programs that evaluate resistant bacteria across food animals, retail meat, and human health interfaces, supporting high reliance on quality-assured AST in stewardship programs. Canada similarly emphasizes integrated surveillance, veterinary oversight, and prudent use policies, while Mexico is strengthening veterinary diagnostic capacity in the context of livestock production, food safety, and cross-border trade. Brazil’s large poultry, beef, and swine sectors make veterinary AST important for export assurance, herd health, and zoonotic pathogen monitoring.In Europe, the United Kingdom, Germany, France, Italy, and Spain operate under strong antimicrobial stewardship expectations and regulatory controls that encourage responsible prescribing and laboratory confirmation. The United Kingdom has emphasized veterinary antimicrobial use reduction and surveillance reporting, while Germany and France maintain advanced diagnostic and regulatory systems for food animal and companion animal health. Italy and Spain, with significant livestock and companion animal sectors, continue to integrate AST into stewardship and food safety programs. Russia’s veterinary AST landscape is shaped by livestock production, regional laboratory modernization, and the need for surveillance of bacterial diseases relevant to animal health and food systems.
China’s veterinary AST needs are driven by large-scale swine, poultry, aquaculture, and companion animal populations, alongside continued reforms in antimicrobial use governance and surveillance. India faces substantial demand due to its dairy, poultry, aquaculture, and companion animal sectors, with diagnostic standardization and laboratory access remaining priorities. Japan and South Korea have advanced veterinary healthcare systems, food safety programs, and AMR action plans that support structured testing and surveillance. Australia maintains strong biosecurity, antimicrobial stewardship, and veterinary diagnostic standards, with AST playing a central role in companion animal medicine, livestock health, and monitoring of resistant organisms relevant to public health.
Actionable Recommendations for Veterinary AST Leaders
Industry leaders should prioritize validated veterinary-specific AST workflows that align with recognized standards, quality control requirements, and clinically relevant interpretive criteria. Laboratories and diagnostic solution providers can improve adoption by offering species-appropriate antimicrobial panels, clear reporting formats, and decision support that distinguishes between clinical breakpoints, epidemiological cutoffs, and resistance markers. Investments in staff training, proficiency testing, and laboratory accreditation are essential to maintain confidence in susceptibility results.Stakeholders should also strengthen One Health data interoperability. Veterinary AST results gain greater value when they can be connected to antimicrobial use records, farm management data, clinical outcomes, and public health surveillance systems while protecting data privacy and commercial confidentiality. Digital reporting tools should be designed to reduce administrative burden for veterinarians and laboratories, not add complexity.
For AI and rapid diagnostic implementation, leaders should follow a validation-first approach. New tools should be evaluated against reference phenotypic methods, tested across relevant animal species and bacterial pathogens, and monitored for performance drift. Commercial and institutional strategies should focus on practical use cases: faster treatment decisions, outbreak detection, resistance trend monitoring, improved antimicrobial panel selection, and stewardship compliance.
Research Methodology for Evidence-Based Veterinary AST Analysis
A robust research methodology for veterinary antimicrobial susceptibility testing analysis should combine secondary research, expert validation, and structured evidence review. Reliable sources include peer-reviewed veterinary microbiology publications, AMR surveillance reports, regulatory guidance, laboratory standards, national action plans, food safety authorities, and international One Health frameworks. Evidence should be assessed for geographic relevance, species specificity, pathogen coverage, test method validity, and consistency with current veterinary interpretive criteria.Primary insights can be gathered through interviews with veterinary microbiologists, diagnostic laboratory directors, companion animal clinicians, livestock veterinarians, food safety specialists, regulatory experts, and antimicrobial stewardship professionals. Findings should be triangulated across diagnostic practice, regulatory requirements, clinical use cases, and surveillance needs. Methodological rigor requires exclusion of unsupported claims, clear distinction between phenotypic AST and molecular resistance detection, and careful review of whether cited breakpoints and test methods are appropriate for the animal species and pathogen under discussion.
The most credible analysis avoids speculative market sizing and instead focuses on verifiable adoption drivers, regulatory changes, technology readiness, laboratory quality systems, and evidence-based stewardship practices. Continuous monitoring is needed because veterinary AST evolves with new breakpoints, updated antimicrobial use rules, emerging resistance mechanisms, and advances in diagnostic automation and genomic epidemiology.
Conclusion: Veterinary AST as a One Health Imperative
Veterinary antimicrobial susceptibility testing is central to responsible animal healthcare, food safety, and One Health antimicrobial resistance control. As veterinary medicine moves away from empirical antimicrobial use and toward evidence-based treatment, AST provides the laboratory foundation for targeted therapy, resistance monitoring, and stewardship accountability. The field is being reshaped by standardized methods, veterinary-specific interpretive criteria, digital surveillance, rapid diagnostics, and carefully validated AI-enabled tools.Regional and country-level adoption patterns vary according to diagnostic infrastructure, livestock intensity, companion animal healthcare maturity, regulation, and AMR surveillance priorities. Across all geographies, the strongest opportunities lie in improving laboratory quality, expanding access to validated testing, connecting AST data with stewardship programs, and ensuring that results are interpreted in ways that are clinically meaningful for animal species and production systems.
The future of veterinary AST will be defined by speed, standardization, interoperability, and trust. Stakeholders that invest in quality-assured diagnostics, One Health data integration, and responsible technology deployment will be best positioned to support veterinarians, producers, regulators, and public health systems in reducing antimicrobial resistance risks while safeguarding animal welfare and food security.
Additional Product Information:
- Purchase of this report includes 1 year online access with quarterly updates.
- This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
7. Veterinary Antimicrobial Susceptibility Testing Market, by Test Type
8. Veterinary Antimicrobial Susceptibility Testing Market, by Animal Type
9. Veterinary Antimicrobial Susceptibility Testing Market, by Pathogen Type
10. Veterinary Antimicrobial Susceptibility Testing Market, by Sample Type
11. Veterinary Antimicrobial Susceptibility Testing Market, by Product Type
12. Veterinary Antimicrobial Susceptibility Testing Market, by End User
13. Veterinary Antimicrobial Susceptibility Testing Market, by Region
14. Veterinary Antimicrobial Susceptibility Testing Market, by Group
15. Veterinary Antimicrobial Susceptibility Testing Market, by Country
16. Competitive Landscape
17. Company Profiles
List of Figures
List of Tables
Companies Mentioned
- Accelerate Diagnostics, Inc.
- Alifax S.r.l.
- Alveo Technologies, Inc.
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Biogal Galed Laboratories
- Bioguard Corporation
- bioMérieux SA
- Bruker Corporation
- Condalab S.L.
- Creative Diagnostics
- Eurofins Scientific SE
- Hardy Diagnostics
- HiMedia Laboratories Private Limited
- Liofilchem S.r.l.
- Mast Group Ltd.
- Microbiologics, Inc.
- QIAGEN N.V.
- QuantaMatrix Inc.
- SSI Diagnostica A/S
- Thermo Fisher Scientific Inc.
- Zoetis Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 180 |
| Published | July 2026 |
| Forecast Period | 2026 - 2032 |
| Estimated Market Value ( USD | $ 1.6 Billion |
| Forecasted Market Value ( USD | $ 2.66 Billion |
| Compound Annual Growth Rate | 8.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
